Two Low-Dose Levonorgestrel Intrauterine Contraceptive Systems

Nelson, Anita L.; Apter, Dan; Hauck, Brian; Schmelter, Thomas; Rybowski, Sarah; Rosen, K.; Gemzell‐Danielsson, Kristina

doi:10.1097/aog.0000000000000019

Cited by 137 publications

(171 citation statements)

References 11 publications

(8 reference statements)

Supporting

Mentioning

147

Contrasting

Unclassified

Order By: Relevance

“…Such a comparison is limited by differences in study participant populations. The lower dose levonorgestrel IUS studies included a mix of women from 11 countries (Argentina, Canada, Chile, Finland, France, Hungary, Mexico, the Netherlands, Norway, Sweden, and USA) whereas this current study was performed exclusively in the USA [9]. Additionally, the lower dose levonorgestrel IUS studies had 39.2% nulliparous women with a mean BMI of 25.3 kg/m 2 [9] whereas this current study had 57.5%…”

Section: Discussionmentioning

confidence: 91%

Bleeding patterns for the Liletta^® levonorgestrel 52 mg intrauterine system

Schreiber

Teal²,

Blumenthal

et al. 2018

The European Journal of Contraception & Reproductive Health

View full text Add to dashboard Cite

Purpose: Evaluate bleeding patterns for the Liletta V R levonorgestrel 52 mg intrauterine system (IUS) using the World Health Organization Belsey definitions. Material and methods: This prospective multicenter trial evaluates the efficacy and safety of Liletta V R (Clinicaltrials.gov NCT00995150). We evaluated bleeding patterns for 1700 nulliparous and multiparous women using a daily diary completed by participants for the first 2 years and by questionnaire every 3 months thereafter. We assessed amenorrhea rates over 3 years and the proportion of subjects with infrequent, frequent, prolonged and irregular bleeding per 90-day reference period over 2 years for the entire study population as well as comparing nulliparous and parous women and obese and non-obese women. Results: Amenorrhea rates at 1 and 3 years in levonorgestrel 52 mg IUS users were 19 and 37%, respectively. The infrequent bleeding rate increased from 14% in the first 90 days to 30% at the end of Year 1, and was maintained at the same rate through Year 2. Frequent, prolonged and irregular bleeding declined to low levels by the end of the first year. Discontinuation for bleedingrelated complaints occurred in 35 (2.1%, 95% CI 1.3-2.7%) women during the first 36 months; only one subject discontinued for amenorrhea (in Year 2). Outcomes did not vary for nulliparous versus parous or obese versus non-obese women. Conclusions: Among Liletta users, amenorrhea and infrequent bleeding become more prevalent over time and amenorrhea rates continue to increase after the first year of use. Bleeding patterns do not differ significantly by parity or by obesity-status. Discontinuation for bleeding concerns is uncommon with this product. ARTICLE HISTORY

show abstract

Section: Discussionmentioning

confidence: 91%

Bleeding patterns for the Liletta^® levonorgestrel 52 mg intrauterine system

Schreiber

Teal²,

Blumenthal

et al. 2018

The European Journal of Contraception & Reproductive Health

View full text Add to dashboard Cite

show abstract

“…Использование ЛНГ-ВМС не приводит к гипер-или дислипидемии. Кроме того, результаты клинических исследований, продолжавшихся в течение 5 лет, свидетельствовали о том, что ЛНГ-ВМС не оказывает отрицательного влияния на показатели артериального давления, массу тела [18][19][20][21].…”

Section: Modern Approaches To Contraception For Women In Perimenopausunclassified

Modern approaches to contraception for women in perimenopausal period (literature review)

Pestrikova¹,

Yurasova²,

Yurasov³

2016

Probl. reprod.

View full text Add to dashboard Cite

Перименопаузальный период -период жизни женщины, характеризующийся естественным воз-растным угасанием функций половой системы. Включает переходный период, менопаузу и 2 года постменопаузального периода [1].Выбор контрацепции в возрасте старше 45 лет, т.е. в так называемом «переходном» периоде, пред-ставляет нередко весьма сложную задачу в силу осо-бенностей этого возрастного периода, связанного с неизбежными процессами постепенного угасания функции яичников, наличием ряда гинекологиче-ских и экстрагенитальных заболеваний, появлением вегетососудистых и других ранних симптомов кли-мактерия. Несмотря на то что в этом возрастном пе-риоде фертильность снижается, случаи рождения детей у женщин старше 45 лет не так уж и редки. По

show abstract

“…The new Jaydess (Skyla ® in the USA), having a transverse arm length of 28 mm is conceived for that reason. Initial clinical trials are encouraging [16], but this 28 mm transverse arm may still be too long for many women as the IUD cavity width is less than 24 mm in many women. Figure 6 illustrates the width of the uterine cavity in nulliparous women.…”

Section: Implications For Iud Usersmentioning

confidence: 99%

How to become Proficient with Insertion of Frameless IUDS?

Wildemeersch¹

2016

OGIJ

View full text Add to dashboard Cite

show abstract

Two Low-Dose Levonorgestrel Intrauterine Contraceptive Systems

Abstract: : I.

Cited by 137 publications

References 11 publications

Bleeding patterns for the Liletta^® levonorgestrel 52 mg intrauterine system

Bleeding patterns for the Liletta^® levonorgestrel 52 mg intrauterine system

Modern approaches to contraception for women in perimenopausal period (literature review)

How to become Proficient with Insertion of Frameless IUDS?

Contact Info

Product

Resources

About

Two Low-Dose Levonorgestrel Intrauterine Contraceptive Systems

Abstract: : I.

Cited by 137 publications

References 11 publications

Bleeding patterns for the Liletta® levonorgestrel 52 mg intrauterine system

Bleeding patterns for the Liletta® levonorgestrel 52 mg intrauterine system

Modern approaches to contraception for women in perimenopausal period (literature review)

How to become Proficient with Insertion of Frameless IUDS?

Contact Info

Product

Resources

About

Bleeding patterns for the Liletta^® levonorgestrel 52 mg intrauterine system

Bleeding patterns for the Liletta^® levonorgestrel 52 mg intrauterine system